Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma

Authors

• Keri Toner, Children's National Hospital
• Carl E Allen, Baylor College of Medicine
• Shweta Jain, Seagen Inc.
• Brad Kahl, Washington University School of Medicine in St. Louis
• John Leonard, Weill Cornell Medical College
• Heather Wasserstrom, Bristol Myers Squibb
• Jonathan W Friedberg, University of Rochester
• Nita L Seibel, National Institutes of Health
• Kara Kelly, University at Buffalo

Journal

EJHaem

Publication Date

11-1-2023

Volume

4

Issue

4

First Page

921

Last Page

926

Document Type

Open Access Publication

DOI

10.1002/jha2.787

Rights and Permissions

Toner K, Allen CE, Jain S, Kahl B, Leonard J, Wasserstrom H, et al. Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma. eJHaem. 2023;4:921–926. https://doi.org/10.1002/jha2.787 © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Toner, Keri; Allen, Carl E; Jain, Shweta; Kahl, Brad; Leonard, John; Wasserstrom, Heather; Friedberg, Jonathan W; Seibel, Nita L; and Kelly, Kara, "Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma." EJHaem. 4, 4. 921 - 926. (2023).
https://digitalcommons.wustl.edu/oa_4/6947